MedTrace Logo

A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada

NCT02367222 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-05-12

No results posted yet for this study

Summary

The purpose of this database study is to assess if Arepanrix™ vaccination during the 2009 pandemic was associated with an increased risk of multiple sclerosis (MS) in Manitoba, Canada.

Conditions

Interventions

OTHER

Exposed to Arepanrix™ Cohort

Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..

OTHER

Unexposed to Arepanrix™ Cohort

Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.

Sponsors & Collaborators

Principal Investigators

  • Salah Mahmud, MD, PhD · Community Health Sciences, University of Manitoba

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-08-31
Completion
2015-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02367222 on ClinicalTrials.gov